Abstract 575
Background
People with dementia have poorer cancer outcomes than those without. Little information exists concerning implications of comorbid cancer-dementia for people having cancer treatment in an ambulatory care setting. The purpose of this focused ethnography is to characterise the environment, behaviour and processes that comprise the setting, and to explore what constitutes ‘good care’ in this context.
Trial design
The aim of this focused ethnography is to establish an empirically-based conceptual foundation to inform development of innovations to improve the way treatment and support is offered to people with dementia having cancer treatment. Objectives include: Understanding the physical fabric of the ambulatory care environment, and how this shapes patterns of behaviour and processes; Understanding the actions of those involved in the receipt or provision of care for people with dementia having cancer treatment, through exploration of interactions, perceptions, and language. Understanding the processes involved in care delivery, and how these shape treatment and support offered to patients. Identify characteristics that constitute ‘good care’ and gain an understanding of barriers and facilitators. Identify which aspects of the ambulatory care setting are amenable to modification to meet the needs of this complex population. This project will allow formation of a rich picture of the cultural context in which behaviour, environment and processes are situated, and identify ways in which the organisation of care might be structured to provide a person-centred service for people with dementia. Participants: Participation will be invited from people with dementia having cancer treatment (n ≤ 10), informal carers (n ≤ 10), and staff members (oncologists, nurses, radiographers, support workers, administrative staff, and allied health professionals) (n ≤ 30). Methods: Data will be collected via observations, interviews and document analysis. Data will be analysed using constant comparison, informed by the analytic tradition of grounded theory (Glaser & Strauss 1967), to allow the researchers to establish an empirically-based conceptual and theoretical foundation that is grounded in the original data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Naomi Farrington.
Funding
National Institute for Health Research, United Kingdom.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1908 - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4058 - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients
Presenter: Anouk de Jong
Session: Poster Display session 3
Resources:
Abstract
2226 - Spatial-Temporal Change in Quantitative Total Bone Imaging (QTBI) and Circulating Tumor Cells (CTCs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide (ENZA)
Presenter: Glenn Liu
Session: Poster Display session 3
Resources:
Abstract
5795 - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.
Presenter: Susanne Osanto
Session: Poster Display session 3
Resources:
Abstract
899 - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Presenter: Jungreem Woo
Session: Poster Display session 3
Resources:
Abstract
3094 - Circulating tumor cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
2527 - Circulating Tumor Cells (CTC) count and Prostate-Specific Antigen (PSA) response measures in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients (pts) treated with Docetaxel (Doc)
Presenter: Rebeca Lozano Mejorada
Session: Poster Display session 3
Resources:
Abstract
6106 - Assessing the clinical relevance of drug–drug interactions (DDI) with darolutamide (DARO)
Presenter: Christian Zurth
Session: Poster Display session 3
Resources:
Abstract
2237 - KEYNOTE-921: phase 3 study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
2241 - KEYNOTE-641: Phase 3 Study of Pembrolizumab (pembro) Plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: Julie Graff
Session: Poster Display session 3
Resources:
Abstract